Nitric Oxide Releasing Prodrugs of Therapeutic Agents
申请人:SATYAM Apparao
公开号:US20110263526A1
公开(公告)日:2011-10-27
The present invention relates to nitric oxide releasing prodrugs of known drugs or therapeutic agents which are represented herein as compounds of formula (I) wherein the drugs or therapeutic agents contain one or more functional groups independently selected from a carboxylic acid, an amino, a hydroxyl and a sulfhydryl group. The invention also relates to processes for the preparation of the nitric oxide releasing prodrugs (the compounds of formula (I)), to pharmaceutical compositions containing them and to methods of using the prodrugs.
Oral pharmaceutical compositions containing cyclodextrins as taste masking agent
申请人:——
公开号:US20040115258A1
公开(公告)日:2004-06-17
The application discloses oral pharmaceutical compositions which are tasted in the mouth during administration. Fast-dissolving tablets, chewable tablets and effervescent dispersions are exemplified. To mask the taste of unpleasant-tasting active ingredients, it has been found that blending with cyclodextrin without the conventional complex formation is effective. Consequently more economical modes of manufacture such as simple granulation and dry blending can be used.
Microspheres are produced by contacting a solution of a macromolecule or small molecule in a solvent with an antisolvent and a counterion, and chilling the solution. The microspheres are useful for preparing pharmaceuticals, nutraceuticals, cosmetic products and the like of defined dimensions.
HETERODIMER COMPOSITIONS AND METHODS FOR THE TREATMENT OF OCULAR DISORDERS
申请人:Ripple Therapeutics Corporation
公开号:US20210347809A1
公开(公告)日:2021-11-11
Described herein are processable compositions comprising at least one moiety that is processable in its free form. Also described herein are compositions and methods for the treatment of ocular diseases or disorders including glaucoma, blepharitis, ocular inflammation, diabetic macular edema, posterior inflammation, anterior inflammation, macular degeneration (e.g., wet macular degeneration (AMD) or dry AMD), post-cataract surgery, and retinal vein occlusion. Said compositions and methods comprise steroids and prostaglandins which demonstrate anti-inflammatory activity, intraocular pressure (IOP) lowering, and/or other desirable activities. Injection of said compositions in the eye provides therapeutic benefit to patients suffering from ocular disorders.
Identification of steroid isoxazole isomers marketed as designer supplement
作者:Maria K. Parr、Michael Gütschow、Jörg Daniels、Georg Opfermann、Mario Thevis、Wilhelm Schänzer
DOI:10.1016/j.steroids.2008.11.006
日期:2009.3
The product Orastan-A from Gaspari Nutrition was analyzed for its steroid content. According to the labeling, it is supposed to contain "5a-Androstano[2,3-c]furazan-17b-tetrahydropyranol ether", also called furazadrol-THP ether. The GC-MS analyses of the liberated steroids (after extraction from the capsule matrix and cleavage of the THP ether, TMS-derivative and underivatized) revealed mass spectra